Related Experiment Video
Updated: Apr 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Toxicity patterns with immunomodulating antibodies and their combinations
John B A G Haanen1, Hans van Thienen1, Christian U Blank1
1Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Abstract:
Immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), but also LAG-3 and TIM-3, are involved in regulation of peripheral tolerance in order to prevent autoimmunity. Blocking of these cell surface proteins by antibodies has resulted in remarkable anti-tumor immunity; however this immunity is accompanied by immune-related adverse reactions (irAEs), resembling autoimmune diseases. Hence, treatment with immunosuppressive drugs is highly effective and resolves the symptoms caused by these adverse events rapidly. In this review, toxicity patterns observed with immune checkpoint blockade are described for single-agent and combination treatments.
Insights
Immune checkpoint inhibitors like CTLA-4 and PD-1 block self-tolerance, enhancing anti-tumor immunity but causing autoimmune side effects. Immunosuppressive drugs effectively manage these immune-related adverse reactions.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Immune checkpoint molecules, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), LAG-3, and TIM-3, are crucial for maintaining peripheral tolerance and preventing autoimmunity.
- Antibody-mediated blockade of these immune checkpoints unleashes potent anti-tumor immunity.
Purpose of the Study:
- To review the toxicity patterns associated with immune checkpoint blockade therapies.
- To describe adverse events resulting from both single-agent and combination immune checkpoint inhibitor treatments.
Main Methods:
- Literature review of immune checkpoint blockade therapies.
- Analysis of immune-related adverse reactions (irAEs) observed in clinical settings.
Main Results:
- Immune checkpoint blockade, while effective against cancer, frequently leads to irAEs that mimic autoimmune diseases.
- Combination therapies may present distinct or amplified toxicity profiles compared to single agents.
Conclusions:
- Understanding toxicity patterns is essential for managing patients undergoing immune checkpoint blockade.
- Prompt treatment with immunosuppressive drugs is effective in resolving irAEs and their associated symptoms.
More Related Videos
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
Drug Toxicity: Allergic Reactions
Drug toxicity: Idiosyncratic Reactions
Drug toxicity: Drug–Drug Interaction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Toxicity: Dose-Dependent Reactions
Drug Toxicity: Overview